TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Harvard Medical School
Curated by ChEMBL
Harvard Medical School
Curated by ChEMBL
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Harvard Medical School
Curated by ChEMBL
Harvard Medical School
Curated by ChEMBL
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Harvard Medical School
Curated by ChEMBL
Harvard Medical School
Curated by ChEMBL
Affinity DataKi: 1.20E+3nMAssay Description:Inhibition of UCHL1More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Harvard Medical School
Curated by ChEMBL
Harvard Medical School
Curated by ChEMBL
Affinity DataKi: 1.40E+3nMAssay Description:Inhibition of UCHL1More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Harvard Medical School
Curated by ChEMBL
Harvard Medical School
Curated by ChEMBL
Affinity DataKi: 1.50E+3nMAssay Description:Inhibition of UCHL1More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Harvard Medical School
Curated by ChEMBL
Harvard Medical School
Curated by ChEMBL
Affinity DataKi: 2.00E+3nMAssay Description:Inhibition of UCHL1More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Harvard Medical School
Curated by ChEMBL
Harvard Medical School
Curated by ChEMBL
Affinity DataKi: 2.80E+3nMAssay Description:Inhibition of UCHL1More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Harvard Medical School
Curated by ChEMBL
Harvard Medical School
Curated by ChEMBL
Affinity DataKi: 3.60E+3nMAssay Description:Inhibition of UCHL1More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Harvard Medical School
Curated by ChEMBL
Harvard Medical School
Curated by ChEMBL
Affinity DataKi: 5.30E+3nMAssay Description:Inhibition of UCHL1More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Harvard Medical School
Curated by ChEMBL
Harvard Medical School
Curated by ChEMBL
Affinity DataKi: 1.00E+4nMAssay Description:Inhibition of UCHL1More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Harvard Medical School
Curated by ChEMBL
Harvard Medical School
Curated by ChEMBL
Affinity DataKi: 1.10E+4nMAssay Description:Inhibition of UCHL1More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Harvard Medical School
Curated by ChEMBL
Harvard Medical School
Curated by ChEMBL
Affinity DataKi: 2.00E+4nMAssay Description:Inhibition of UCHL1More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Harvard Medical School
Curated by ChEMBL
Harvard Medical School
Curated by ChEMBL
Affinity DataKi: 2.00E+4nMAssay Description:Inhibition of UCHL1More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Harvard Medical School
Curated by ChEMBL
Harvard Medical School
Curated by ChEMBL
Affinity DataKi: >3.00E+4nMAssay Description:Inhibition of UCHL1More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Harvard Medical School
Curated by ChEMBL
Harvard Medical School
Curated by ChEMBL
Affinity DataKi: 3.00E+4nMAssay Description:Inhibition of UCHL1More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Harvard Medical School
Curated by ChEMBL
Harvard Medical School
Curated by ChEMBL
Affinity DataKi: >3.00E+4nMAssay Description:Inhibition of UCHL1More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Harvard Medical School
Curated by ChEMBL
Harvard Medical School
Curated by ChEMBL
Affinity DataKi: >3.00E+4nMAssay Description:Inhibition of UCHL1More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Harvard Medical School
Curated by ChEMBL
Harvard Medical School
Curated by ChEMBL
Affinity DataKi: 3.00E+4nMAssay Description:Inhibition of UCHL1More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Harvard Medical School
Curated by ChEMBL
Harvard Medical School
Curated by ChEMBL
Affinity DataKi: >3.00E+4nMAssay Description:Inhibition of UCHL1More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Harvard Medical School
Curated by ChEMBL
Harvard Medical School
Curated by ChEMBL
Affinity DataKi: 3.00E+4nMAssay Description:Inhibition of UCHL1More data for this Ligand-Target Pair
Affinity DataIC50: 3.20E+3nMAssay Description:Inhibition of human CYP2C9More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: 550nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: 550nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: 550nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: 550nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: 550nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: 550nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: 550nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: 550nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair